Unlabelled: Would there be any difference in the prognosis for patients who presented, for example, 8% or 88% tumor necrosis induced by chemotherapy, even though both individuals were considered to be poor responders? The aim of this study was to compare the prognoses for different histological grades (Huvos grade I versus grade II), consequent to chemotherapy, among patients with primary osteosarcoma that was not metastatic at diagnosis.
Methods: Twenty-four patients admitted to a referral center between 2000 and 2004 were selected for the study. The accumulated chances of survival were calculated using the Kaplan-Meier technique. Huvos grades I and II for necrosis consequent to chemotherapy were evaluated as variables in order to determine their prognostic value, in relation to local recurrence-free survival, metastasis-free survival and overall survival, using the log-rank test.
Results: Comparing Huvos grades I and II, the following P values for survival were attained: local recurrence-free survival (P = 0.731), metastasis-free survival (P = 0.596) and overall survival (P = 0.669).
Conclusion: In this series, Huvos grades I and II did not have any comparative prognostic value and had similar behavior.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799283 | PMC |
| http://dx.doi.org/10.1016/S2255-4971(15)30256-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The standard treatment for localized osteosarcoma is neoadjuvant chemotherapy before surgery, followed by adjuvant chemotherapy. Our aim was to report the rate of histopathological response to neoadjuvant chemotherapy for the treatment of extremity osteosarcoma in Vietnam.
Methods: We performed a retrospective study of stage II conventional osteosarcoma patients under 40 years-old who received MAP regimen as neoadjuvant chemotherapy at the Vietnam National Cancer Hospital between June 2019 and June 2022.
Preoperative prediction of high-grade osteosarcoma response to neoadjuvant therapy based on a plain CT radiomics model: A dual-center study.
J Bone Oncol
August 2024
Department of Radiation, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China.
Objective: To develop a model combining clinical and radiomics features from CT scans for a preoperative noninvasive evaluation of Huvos grading of neoadjuvant chemotherapy in patients with HOS.
Methods: 183 patients from center A and 42 from center B were categorized into training and validation sets. Features derived from radiomics were obtained from unenhanced CT scans.
Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF.
Virchows Arch
June 2024
Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga/Dr, Soetomo General Academic Hospital, Mayjen Prof. Dr. Moestopo 6-8, Airlangga, Gubeng, Surabaya, East Java, Indonesia.
High-grade osteosarcoma, a primary malignant bone tumour, is experiencing a global increase in reported incidence with varied prevalence. Despite advances in management, which include surgery and neoadjuvant chemotherapy often an unsatisfactory outcome is found due to poor or heterogeneous response to chemotherapy. Our study delved into chemotherapy responses in osteosarcoma patients and associated molecular expressions, focusing on CD95 receptor (CD95R), interferon (IFN)-γ, catalase, heat-shock protein (Hsp)70, and vascular endothelial growth factor (VEGF).
View Article and Find Full Text PDFNew gene signature from the dominant infiltration immune cell type in osteosarcoma predicts overall survival.
Sci Rep
October 2023
Department of Cancer Center, The Secondary Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, China.
Article Synopsis
- The immune microenvironment significantly impacts the progression and prognosis of osteosarcoma (OS), but traditional methods focusing solely on immune cell types are inadequate due to tumor heterogeneity.
- Researchers developed a nine-gene prognostic signature from M0 macrophages, using public datasets and advanced statistical models, establishing it as a reliable factor for predicting outcomes in OS patients.
- The study indicated that this gene signature is an independent prognostic tool, showing no major differences in chemotherapy sensitivity between low- and high-risk groups, and highlighted the roles of specific biological pathways in OS progression.
MRI for evaluation of preoperative chemotherapy in osteosarcoma.
Radiography (Lond)
August 2022
Bursa Iznik Devlet Hospital, Istanbul, Turkey.
Introduction: Our study aims to highlight the role of Magnetic Resonance Imaging (MRI) in monitoring the therapeutic response after neoadjuvant chemotherapy in osteosarcoma of the long bones.
Methods: In this retrospective study, data from the Orthopaedics and Internal Medicine Department of Istanbul University Cerrahpasa Hospital was used. We selected the study cohort from our departmental database of patients with biopsy-proven osteosarcoma initially treated with preoperative chemotherapy at Istanbul University Cerrahpasa Hospital from 2010 to 2017.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!